Lv1
58 积分 2025-01-08 加入
LBA50 IMbrave152/SKYSCRAPER-14: A phase III study of first-line tiragolumab (tira) + atezolizumab (atezo) + bevacizumab (bev) vs placebo (pbo) + atezo + bev for patients (pts) with untreated locally advanced or metastatic hepatocellular carcinoma (HCC)
3个月前
已关闭
Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial
3个月前
已完结
IL-33 in COPD: the hunt for responder subgroups
3个月前
已完结
IL-33, inflammation and mucus in COPD: the final FRONTIER?
3个月前
已完结
HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic Centers
3个月前
已关闭
Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma
4个月前
已关闭
[A Study of the Safety of Chemotherapy with Generic Oxaliplatin for the Treatment of Colorectal Cancer]
4个月前
已关闭
Phosphodiesterase 1A overexpression contributes to the progression of renal fibrosis
4个月前
已完结
Indian Experience with Vericiguat: A Review Based upon Case Series
5个月前
已关闭
Vericiguat in Chinese Patients with Heart Failure and Reduced Ejection Fraction: A Real-World Prospective Study
5个月前
已关闭
皖公网安备34019202002308
